EP2984597A1

EP2984597A1 - Sampling and testing device for the human or animal body

Info

Publication number: EP2984597A1
Application number: EP14783290.1A
Authority: EP
Inventors: Sean Andrew Parsons; Steven David Dahl; Jonathan Peter EDGECOMBE
Original assignee: Ellume Pty Ltd
Current assignee: Ellume Pty Ltd
Priority date: 2013-04-12
Filing date: 2014-04-11
Publication date: 2016-02-17
Also published as: CN105264375A; EP2984597A4; WO2014165924A1; WO2014165924A8; JP2016519771A

Abstract

A test device comprises first and second indicia portions. The first indicia portion is configured to indicate the presence or absence of at least one medical condition based on identification of at least one biological entity in the biological sample. The second indicia portion is configured to display all or part of a composite code when the first indicia portion provides an indication of the presence of the medical condition, the code being substantially unique to the test device. The test device includes a printed circuit board and a portion of the composite code corresponds to a serial number of the printed circuit board.

Description

Sampling and tes ting ^

Cross-Reference to Related Applications

The present applicatio claims priorit from. US contimiation-in-part patent application no. 13/861513 filed on 12 April 2013, and from Australian patent application no. 20132044 8 tiled on 12 April 20 3, the contents of which are

incorporated herein by reference in their entirety.

Field

The field of the invention relates to devices and methods for determination of the presence or absence of a biological entity in a human or animal body.

Background

hrimu ochromatography is a well-established testing method used to test for the presence or absence of a antigen (usually a biological protein) in a biological sample. The sample is supplied to a lateral flow test device and flows by capillary action through a label-holding substance which contains a soluble and labelled antibody specific to a particular antigen. If that antigen is present in the sample, an antigen- antibody (labelled) complex is formed which then continues to permeate by capillary action through the device to a test site where the complex is captured by a second antibody attached to the test site. This results in an increase in the density of captured antigen-antibody (labelled) complexes at the test site which results in a visible mark (usually a line) on the test site indicating the presence of the antigen in the sample.

Prior to carrying out the lateral flow test, the test sample must be obtained. This is often an invasive process, particularl if the fluid sample comprises nasal discharge, for example, requiring insertion of a foreign object into a body cavity to obtain the sample.

To obtain nasal discharge (e.g., mucus), a 'nasopharyngeal aspirate' is routinel performed, which involves passing a thin plastic tube into the nose and suctioning discharge from within the nose. Alternatively, a ^£Q-tip' or 'cotton bud' is inserted via the nose into the nasopharynx and then withdrawn with a small sample of discharge. These methods are at present widespread in sampling nasal discharge for testing and are not without risks, including trauma to the nasopharyngeal mucosa and potential injury to the cribriform plate which forms the roof of the nose, separating it from the brain. Additionally, the accuracy of these test methods are highly dependent upon attaining a quality sample and therefore the skill of the person acquiring the sample. As a result these raeihods are carried out by trained health personnel and the associated devices are not necessarily available for sale direct to the public.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or ai l of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date o f each cl aim o f this app i t cation.

Throughout this speci fication the word "comprise", or variations such as "comprises" or "comprising", will, be understood to impl the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Summary

According to a first aspect, the present invention provides a device comprising:

a sampling portion, the sampling portion comprising flexible material adjustably conformable to a art of a human or animal body for receivin a biological sample directl from the body; and

a test portion in fluid engagement with the sampling ortion, the test portion comprising one or more test zones,

wherein the sampling portion and test portion are configured such that at least a portion of the sample received by the sampling portion is transferable to the test portion such as to contact one or more of the test zones, and wherein each test zone is configured to indicate the presence or absence of one or more biological entities in the sample.

According to a second aspect, the present invention provides a method for determination of the presence or absence of a biological entity in a human or animal bod using a device comprising:

a sampling portion, the sampling portion comprising flexible material adjustably conformable to a part of a human or animal body for receiving a biological sample directly from the body; and a test portion in fluid engagement with the sampling portion, the test portion comprising one or more test zones,

wherein the sampling portion and test portion are configured such that at least a portio of the sample received by the sampling portion is transferable to the test portion such as to contact one or more of the test zones, and wherein each test zone is configured to indicate the presence or absence of one or more biological entities in the sample,

the method comprising:

conforming the flexible material of the sampling portion to a part of the huma or animal body;

depositing a biological sample on the sampling portion; and

observ ing a reaction at one or more of the test zones to t he presence or absence of one or more biological entities in the sample.

The device and method may detect the presence or absence of one or more specific biological entities, such, as antigens. The antigens may be found in common respiratory viruses including but not limited to influenza A (including the H1N1 virus subtype). Influenza B, Respiratory Synctial Virus, parainfluenza viruses, adenoviruses, rhinoviruses, corona viruses, coxsackie vkuses, HIV viruses and/or enteroviruses.. The device may also detect specific biological antigens found in bacteria, fungi, protozoa, Helminths, Mycoplasma and prions. The device may also be capable of detecting specific proteins produced by the human or animal body, including but not limited to immunoglobulin, hormone molecules, inflammatory or malignant proteins. The device may comprise a plurality of di ferent test zones so that the presence or absence of different biological entities such as antigens can be tested simultaneously.

The device and method may permit identification of one or more biological entities using existing principles of lateral flow immunochromatograph or other techniques. However, by combing the sampling portion and test portion in. a single device, the device may provide a simple and low cost means for carrying out this process. The sampling portion and test portion may be combined in the device such that fluid engagement exists between the sampling portion and test portion prior to receipt of the sample and therefore, once the samp le is deposited, the user may not need to perform any steps to bring the sampling portion and test portion into fluid engagement. For example, the user may not need to take hold of the test portion and move it into fluid engagement with the sample portion, which could otherwise complicate or adversely affect the testing procedure. In this specification, reference to the sampling portion and testing portion being "in fluid engagement" is intended to radicate the existence of a path between these two portions along which fluid can travel in a controlled, manner. It is conceivable that a removable blocking element such as a release tab may be provided to obstruct the path, e.g. prior to testing. However, even with such a removable blocking element in place, the sampling portion and testing portion can still be considered in fluid engagement.

By providing flexible material adjustably conformable to a part of a human or animal body for receiving a biological sample directly from the body, which material may be at least partially absorbent, the device and method may provide a non-invasive, comfortable, intuitive and convenient means for obtaining and testing the sample. The sampling portion, or at least an absorbent portion thereof, can be configured to receive the sample directly from the body to the extent that no separate collection tool is needed to apply the sample to the sampling portion. Accordingly, collection of a sample using a swab or such like is not necessary, albeit this does not necessarily preclude the use of separate collection tool with the device, should the user choose to use the device in that manner. The device and method may therefore provide a safe, quick and satisfactory alternati ve to invasive sampl ing. The device and method may encourage earlier and more frequent testing for the presence of biological entities in humans or animals. The device and method may be used to test for any biological entity placed directly onto the sampling portion by a method including, but not limited to, a typical, 'nose blow^". The device and method may also allow testing for more tha one biological entity at a time, either increasing the potential diagnosis of multiple organisms for example, or when used to test for the presence of different antigens from a single organism, increasing the diagnostic sensitivity.

The biological sample may be a fluid sample, or may be a substantially solid sample, which is transformed into a fluid upon application of a liquid such as a solution., e.g. a buffer solution, for example. The liquid may act as a carrier for the biological sample. The liquid may be applied to the sampling portion to increase the fluidity of the biological sample. This may be performed to facilitate or improve capillary transfer of the sample, whether the sample is initially solid or fluid, to test zones within the test portion. The liquid may be applied to the sampling portion of the device before or after receipt of the sample.

The liquid may be applied to the sampling portion by a variety of means. For example, the liquid may be applied using a dropper, such as a pipette, or drops may be applied from a squeezable bottle containing the liquid. Alternatively- the liquid may be provided in a reservoir that may be integra with the device. The reservoir may be a sealed reservoir containing the liquid and which is breakable and/or has a removable portion so that the liquid can be released. For example, the reservoir may take the form of a capsule, bubble or blister containing the liquid, or container having at least one thin wall, which is capable of breaking or bursting to release the liquid. The reservoir may have a weakened part to facilitate easier breaking or bursting of the reservoir, and this may be at a pre-deterroined position so that the liquid once released is distributed to an appropriate part of the device. An element maybe provided that is ac natable to break or burst the reservoir, which element may comprise a sharp point, for example.

Preferably the reservoir is provided adjacent the sampling portion of the device.

However, the reservoir ma be provided at a variety of di fferent positions of the devic e.

The flexible material of the sampling portion may be sufficiently supple to bend or fold freely or repeatedly in order to conform to a variety of different shapes of body parts. The flexible material ma be bent or folded repeatedly without being

substantially damaged, cosmetically and/or and functionally.

The flexible material may be conformable to the nasal region of the body, permitting a nasal discharge (e.g., mucus) sample to be provided directly to the sampling portion. The device may provide a means for testing a nasal discharge sample provided directly to the device via an act of nose blowing. The flexible

material of the sampling portion may serve as a facial tissue or handkerchief.

Additionally or alternatively, the flexible materia! may serve as a wipe, allowing a sampl e to be obtained by wiping or dabbing the flexibl e material across a portion of the body. The flexible material may be soft such as to prevent any substantial damage or pain to the body during the wiping, dabbing and/or nose blowing processes.

When used to test a nasal discharge sample, the flexible material may be sufficiently flexible to bend from contact portions adjacent the aia or alar groove of the nose, across the tip of the nose, for example. When used to test a stool sample, the flexible material may be sufficiently flexible to bend to a shape conforming to the intergluteal cleft, for example, in general, however, the flexible material may be conformable to an curved or angled parts of the body, such as parts of the legs, arms, feet, hands, face, head, back, torso and/or genitals, etc. The flexible material may be configured to receive, for testing, one or more of a variety of different types of samples directly from the body. Samples may include, for example, blood, serum, plasma, saliva, sputum, urine, ocular fluid, tears, semen, vaginal discharge, nasal secretions and droplets, ear secretions, perspiration, mucus, stool, andtor amniotic, spinal, wound, or abscess fluid.

In one embodiment, the device ma be configured specifically for testing samples obtained from a respiratory system, such as secretions from the nose, nasopharynx, oral cavity, pharynx, and oropharynx. The secretions may include nasal mucus, droplets from coughing or sneezing, saliva, and pharyngeal and/or

oropharyngeal fluid.

The flexible material may be at least partially absorbent material that can act as a lateral flow medium (e.g. capillary membrane) for transferring at least a portion of the sample from the sampling portion to the test portion. The flexible material may comprise or consist of one or more layers of material and/or padding.

The flexible material may comprise, for example, paper material and or may be in the form of an absorbent pad. The paper material may be tissue paper or lightweight paper or medium weight paper or otherwise and the paper may be natural paper or synthetic paper. The flexible material may comprise, for example, non-woven rayon fabric or non-woven glass-fibre fabric. The flexible material may comprise polymer material and/or fibrous materia! such as wood pu!p, woven or non-woven cellulose or nitrocellulose fabric.

The flexible material may comprise, for example, a cloth material, e.g. a woven or non-woven fabric material. The cloth material may comprise cotton, wool, polyester or acrylics, for example.

The material ma be chosen to be flexible enough to conform to the appropriate body parts and soft enough to perform a wiping, dabbing or blow nose function withou causing discomfort to the body being tested. The choice of material may be a balance between flexibility, softness, strength and ability to function as a lateral flow medium.

The sampling portion and test portion may form all or part of a test layer of the device. The sampling portion and testing portion may be integral with each other or may be two or more separate portions fixed together. The testing portion may comprise a flexible material, e.g. flexible material similar or identical to the flexible material of the sampling portion. The sampling portion and test portion may comprise the same material or different material. For example, the testing portion may comprise harder or more rigid material than the sampling portion, since it may not need to contact the body during the sampling process. One side only of the sampli ng portion or test layer ma be designated as, or configured as, a target side, i.e., a side for contacting the body to / receive the sample. The target side ma comprise markings to indicate the appropriate position for body contact and deposition of the sample. Instructions for carrying out testing using the device and/or interpreting the test results, may also be provided, e.g. printed, on the sampling portion or other region of the test layer.

The device may comprise a cover layer. The cover layer may be attached to. and extend over, one side of the test layer, e.g., the target side of the test layer. A hole in the cover film may be provided so that an area of the sampling portion on that side of the test layer is exposed. Accordingly, a sample may be received by the sampling portion through the hole in the cover layer. The cover layer may be attached to, and extend over, all or part of one side of the test portion of the test layer.

In one embodiment, the plane of the test layer, th e sampling portion may be provided at an inner region of the test layer and the test portion may be provided to the outside of the sampling portion. When a cover layer is provided, in the plane of the cover layer, the hole m ay be located at an inner region of the cover layer so that it al igns with at least a portion of the sampling portion.

The cover layer and hole therein may serve as a guide to ensure that a sample is applied directly to the sampling portion of the device and/or to a targeted area of the sampling portion. Furthermore, the cover layer may act as a barrier to prevent direct application of the sample, and or other fluids or environmental substances, to the test portion, where it might come into contact with the one or more test zones and adversely affect test results. To ensure that a sample is applied to a targeted area of the sampling portion, particularly when the device is to be used to obtain a nasal sample throug nose blowing, finger locatio guides may be provided. The arrangement may be such that a user will locate the device at the correct position with respect to the nose when their fingers are located in the guides, for example.

The cover layer may comprise fluid-resistant material. For example, the cover layer may comprise plastic material. The cover layer may be a flexible material (e.g. a flexible film) so that it does not. prevent the flexible material of the sampling portion from being bent or ma ipulated into an appropriate shape to contact the body during the sampling process. All or part of the cover layer may be translucent or transparent so that a reac tion between the sample and on e of more of th e test zones can be observed through the cover layer. Alternatively or additionally,, the cover layer may comprise one or mor windows arranged to ali gn with the one or more of the test zones so that a reaction between the sample and the test zones can be observed through the wiodows of the cover layer. Instructions for carrying out testing using the device and/or interpreting the test results, may be provided, e.g.. printed, on the cover layer.

The device may comprise a backing layer. The backing layer may be attached to, and extend over, one side of the test layer. The cover film may be provided on the opposite side of th test layer to the target side of the test l ayer. Th e backing layer may ensure that the sample received by the sampling portion does not leak from the sampling portion, e.g., onto a hand or other surface, and is instead directed toward the test portion of the test lay er.

The backing layer may comprise fluid-resistant material. For example, the backing layer may comprise plastic material. The backing layer may be flexible material (e.g. a flexible- film) so that it does not prevent the flexible material of the sampling portion from being bent or manipulated into an appropriate shape to contact the body during the sampling process. The backing layer may comprise slide resistant material, e.g., rubbery material, to allow easier gripping of the device by a person performing the testing. Furthermore, the slide resistant material may permit the device to grip to a surface (e.g. a table or bench top), whilst the reaction of the one or more test zones is observed. Ail or part of the backing layer may be translucent or transparent so that a reaction between the sample and one of more of the test zones can be observed through the hacking layer. Alternatively or additionally, the backing layer may

comprise one or more windows arranged to align with the one or more of the test zones so that a reaction between the sample and the test zones can be observed through the windows of the backing layer. Instructions for carrying out testing using the device and/or interpreting the test results, may be provided, e.g. printed, on the backing layer

The device may comprise absorbent material to prevent fluid flowing through outer edges of the test layer and onto a users hand or the floor, etc. The absorbent material may be a strip of absorbent material located around the periphery of the device. The absorbent material may be integral to, or connected to, outer regions of one or more of the cover layer, test layer and backing layer. Alternatively, the absorbent material may be provided as an independent element of the device. For example, an additional layer comprising the absorbent material may be prov ded. The additional layer may extend beyond the outer edges of one or more of the cover layer, test laye and backing layer. The absorbent material may be more absorbent, e.g. have a greate fluid retention capacity, than the test layer.

The cover layer may extend to and align with outer edges of the test layer. As an alternative, the cover may extend only partway to the edges of the test layer, in the latter arrangement, an outer region, e.g. outer strip, of the test layer may be exposed beyond the outer edges of the cover layer. The outer region of the test layer may provide the aforementioned absorbent material to prevent fluid flowing through the outer edges of the test layer.

The device may be substantially flat The device ma be a cloth-like device.

That is, the entire device may be a substantially flat, pliable element, easily handled and manipulated by a patient or other person carrying out the testing. The test layer, cover layer and/or backing layer may each comprise a single layer of material, only or comprise multiple layers of material.

The device may be foldable such that, following deposition of a sample on the sampling portion, the sampling portion including the sample can be hidden from view. This may be desirable as a sample may be considered unsightly. Whilst the sample is visible, the user may be reluctant to pass the device to another person, e.g., a clinician, for analysis of test results. The device may be folded so that only the backing layer is visible, for example. The device may be foldable in half or other manner, to achieve the desired effect. The device ma comprise one or more fold lines to indicate the appropriate position for folding.

If liquid, such as buffer solution, for increasing the fluidity of the biological sample, is provided in a reservoir in accordance with the preceding discussions, the reservoir may be configured to release the liquid upon folding of the device. For example, the reservoir may be configured to burst or break during or after folding of the device. The process of folding the device alone may be sufficient to cause the release of the liquid. Alternatively, release of the liquid may be achieved by further user intervention, such as the user applying force to the reservoir after folding, using their fingers for example. Alternatively, release of the liquid may be achieved by a combination of the folding process and the user applying additional force to the reservoir. The reservoir m ay be located across or adjacent a fold line of the device. Accordingly, once the device is folded, a user may have easier access to the reservoir as the reservoir may be located at the edge of the folded de vice. The reservoir may be folded upon folding' of the device. This may allow a user to press opposite sides of the folded reservoir against one another to force the reservoir to release the liquid.

As an alternative, the device may be substantially pre-folded, For example, the device may take generally., a butterfly configuration. To this extent, the device may include two flexible wings at least partially forming the sampling portion, and a central housing (spine) located between the two wings. The wings may be relatively pivotable or flexible about the housing.

In general, whether or not the device takes a butterfly configuration, a housing may be provided in the device and arranged to at least partially enclose and/or protect one or more components of the device. For example, the housing may enclose at least partially the testing portion of the device, the l iqu id reservoir and/or other elem ents discussed herein . The housing may be substantially rigid and may prevent or reduce the likelihood of damage to the test portion, liquid reservoir and or other elements enclosed therein. When the housing comprises the testing portion, the housing may include one or more openings or transparent portions to permit observation of the results of testing.

The device may comprise one or more lateral flow test strips, e.g. conventional lateral flow strips that are already available. The test strips may be Quickvue*^' influenza A and B test strips produced by Quids! Corporation, or BinaxNOW® influenza A and B test strips produced by Inverness Medical innovations. Inc., for example. Each test strip may provide a respective test portion of the device. Each test strip may be incorporated into the device such as to be i fluid engagement with the sampling portion. The device may provide, in essence, an adapter for one or more conventional lateral flow test strips such as to allow convenient and comfortable deposition of a sample that can be transferred to the one of more test strips. The test strips may be located in a housing of the device, in one embodiment, the device may be confi gured to allow insertion of one or more lateral flow test strips into the device that have been selected by the user or manufacturer dependent on the desired testing to be carried out.

In one embodiment, an actuator mechanism may be provided to release liquid from the reservoir. The actuator mechanism may comprise, or interact with, a piercing element, such that, upo operation of the actuator mechanism, the piercing element may burst tire reservoir, for example. The actuator mechanism may comprise an actuation element that is moveable, e.g., slidable or pivotable, relative to the sampling portion and/or the testing portion. The actuation element may have additional or alternative functions. For example, the actuator element may be configured to spread the sample, e.g., prior to causing release of the fluid from the reservoir. As another example, the actuator element may be configured to activate an LED, in accordance with, subsequent discussions herein.

According to a third aspect, the present invention pro vides a device comprising; a sampling portion for receiving a biological sample directly from the body; a test portion in fluid engagement with the sampling portion, the test portion comprising one or more test zones; and

a sealed reservoir containing liquid,

wherein the sampling portion and test portion are configured such that at least a portio of the sample received by the sampling portion is transferable to the test portio such as to contact one or more of the test zones, and wherein each test zone is configured to indicate the presence or absence of one or more biological entities in the sample; and

wherein the device is foldable and the sealed reservoir is configured such that, after or during folding, the liquid is releasable from the reservoir to increase the fluidit of the biological sample.

The device accordi g to the third aspect may have any one or more features of the device described with respect to the first, and second aspects of the invention. For example, the reservoir of the device may be a capsule, bubble or blister, where the liquid is released from the reservoir through a force applied to the reservoir upo folding and/or through the application of an additional force by the user after or during folding. As another example, the sampling portion may comprise flexible material adjustably conformable to a part of a hitman or animal body for receiving a biological sample directly from the body. Nonetheless, it is conceivable that the sampling portion in this third aspect may exhibit less flexibility and may receive a biological sample that is dropped onto the sampling portion, or applied to the sampling portion using a tool such as a dropper or device such as a cotton bud.

In any of the preceding aspects, the device may comprise one or more fixation devices to maintain the device in a folded configuration. The fixation devices ma be releasable or non-releasable. The fixation devices may comprise hook and loop fasteners (Velcro^IM), clips, adhesive or otherwise. The fixation devices may be provided at edges and/or corners of the device for example. The fixation devices may be pro vided on any one or more of the cover layer, test layer and backing layer. If the device is square or rectangular in shape, for example, the fixation devices may be provided at or adjacent two corners of the device, and complimentary fixation devices may be provided at or adjacent the other two corners of the device such that, upon folding the device in hal the fixation devices will co-operate and fix to each other. If the fixation devices are e.g., adhesive, however, rather than fixation devices fixing to each other, the fixation devices may fix directly to another portion of the device, e.g., to one or more of the cover, test and backing layers of the device.

The device may be maintained, in the folded configuration during observation of the test results. Observation may be made through one or more translucent or transparent portions of the backing layer or housing, or one or more windows provided in the backing layer or housing, for example.

The sampling portion of the device, configured to conform to the body to receive the sample, may ha ve a minimum surface area of about 5 cm² or 10 cm² or 20 cm² or 30 cm² or 40 cm² or 50 cm or 100 cm² and may have a minimum diameter, or length and/or width, of about 2 cm or 3 cm or 4 cm 5 cm or 6 cm or 7cm or 10 cm.

The device, for example when configured as a cloth-like device, may have a minimum surface area on one side of about 100 cm^" or 150 cm" or 200 cm" and may have a minimum diameter, or length and/or width, on one side of about 10 cm or 15 cm or 20 cm.

The test portion of the device may be provided with antigens or antibodies to allow testing for the presence of one or more biological entities using existing principles of lateral flow im unochromatography.

One or more label-holding areas, e.g. coloured label-holding areas containing specific antibodies bound to light visible molecules, may be provided in the test portion. The label-holding areas may be located at the edge or adjacent the edge of the test portion, at the boundary between the test portio and the sample portion. The sample received by the sample portion ma travel via capillary actio through the sample portion and into the test portion where it mixes with the label-holding areas and may form antigen-antibody (labelled) complexes.

The one or more test zones may be spaced from the boundary between the test portion and the sample portion. Accordingly, the sample may encounter the labei- holding areas prior to reaching the test zones. The test zones may comprise stripes (lines), crosses, squares or other shaped regions of the test portion that have been impregnated with antibodies or antigens. Depending upon the biological antigens present in the sample, and the antibodies or antigens at the label-holding areas and the test zones, the sample may become bound at one or more of the test zones, causing a colour change at the test zones. The change in colour may therefore be indicative of the presence or. absence of a specific biological entity in the sample, such as, but not limited to, influenza A or influenza B. A plurality of test zones may he provided such that the presence or absence of a plurality of different types of biological entities in the sample may be tested. Any number of different test zones up to, for example, ten test zones may be pro vided. When the sampling portion i s located at an inner region of the test layer and the testing portion is located to the outer side of the sampling portion, the test zones may be distributed radially about the sample portion, so that the sample, which may spread radially from the sample portion, may contact each test zone independently. In this instance, the labe l -ho l ding areas may be provided across a region of the testing portion encircling the sample portion.

Although the device may use principles of immunochromatography, it is conceived, however, that alternative means of testing could be incorporated into the device.

The device ma provide a rapid diagnosis test device, permitting testing in less than 1 minute or less than 10 minutes of less than 30 minutes or less than one hour, for example. The device may be disposable, configured for one-use only. The device may be provided in sterile packaging prior to use. The device may provide a means for entirely non-invasive testing for the presence or absence of one or more biological entities. The device may be used for testing in the veterinary field as well as in the field of human medicine.

in any of the aspects, upon indicating the presen ce of a biological en tity, the device may be configured to display a code or identifier that is unique to the biological entity and/or the test device.

According to a fourth aspect there is provided a device comprising:

a sampling portion for receiving a biological sample directly from the body; and test portion in fluid engagement, with the sampling portion, the test portion comprising one or more test zones;

wherein the sampling portion and test portion are configured such that at least a portion of the sample received by the sampling portion is transferable to the test portion such as to contact one or more of the test zones, and wherein each test zone is configured to indicate the presence or absence of one or more biological entities in the sample; and

wherein, upon indicating the presence of a biological entity, the device is configured to display a code or identifier that is unique to the biological entity and/or the test device. The device of the fourth aspect may be used to verify a positive test for a biological entity in the sample.

According to a fifth aspect, there is provided a method for verifying a positive test for a biological entity in a biological sample comprising:

testing for the presence of the biological enti ty using a test device wherein, upon determining the presence of a biological entity in the biological sample, the test device displays a code or identifier that is unique to the biological entity and/or the test device; and

submitting the code or identifier to a health sendee.

The device employed in the method of the fifth aspect may be a device according to any one of the preceding aspects.

In the devices of any of the previous aspects, the test zones of the device may display an indicator, e.g. a symbol, to indicate a positive or a negative test result (i.e. to indicate the presence or absence of a specific biological enti ty in. the sample), such as a or a "-" respectively. However, in line with the preceding discussion, the test zones may additionally or alternatively display a unique code or identifier indicative of a positive test result.

The code or identifier may be unique to the biological entity present in the sample and/or unique to the device through which the testing is performed. The code may be a series of letters and/or numbers, such as an alphanumeric code, for example. An identi fier may incl ude one or more other types of symbols, or other elements capable of uniquely identifying the test device and/or the results of testing. The terms code and identifier can be used interchangeably, however, and for simplicity the term "code" is used in subsequent discussions.

Normally the code may be invisible to the user, but may appear when an element defining the code, such as a region of the test portion that has been

impregnated with antibodies or antigens, comes into contact with the specific biological entity that is being tested.

Once the code or identifier is obtained, or "revealed" by the test device, it may be provided to a third party, such as a health service. The health service may be a pharmacy, doctor's surgery, hospital, national health service or otherwise. The code may be provided to the service through a website interface, via phone, email , "SMS" or otherwise. Once the code has been provided, the code may be checked by the service against a database of codes to determine whether the code is a valid code, and/or to determine a biological entity associated with the code. Alternatively, the code may comprise descriptive elements that ca be directly decoded by the service to determine the validity of the code and/or a biological entity associated with the code. The processing of the code may be automated, e.g. using a computer database and/or processor.

By providing the code to the health service, a number of consequences may be achievable. For example, the code may allow national health statistics to be recorded and prevent people from recording false instances of, for example, influenza. The code m y allow for accurate and proper dispensing of appropriate medication to a person presenting the code, e.g., through automated means such as an e-pharraacy. This may have particular advantages during a pandemic. The code may ensure that a legitimate request for medication is being made.

Although the code may be revealed automatically when a positive test result is obtained, as an alternative, the code may be revealed by removing, e.g., peeling back, a portion of the device under which the code may be di splayed, for example. The portio that is removed may be a tab of the cover layer or backing layer of the device, for example. As an alternative, or additionally, the device may comprise a digital reader, which displays the code via a digital output means such as an LCD or LED screen.

in accordance with above-described features of the fourth and fifth aspects, in one embodiment there is provided a medication dispensing system comprising:

at least one test device, the test device comprising:

a test portion adapted to identify at least one biological entity in a biological sample received from a user of the device,

wherein the test device is configured to provide to the user an indication of the presence or absence of at least one medical condition, based on identification of the biological entity in the biological sample, and

wherein, when the test device provides an indication of the presence of the medical condition, the test dev ice is also configured to display all or part of a code that is substantially unique to the test device: and

a health service comprising a processing system, the processing system including an electronic user interface adapted to receive the code and the processing system being adapted to compare the code against a database of codes to determine if the code is a valid code and automatically dispense medication or issue a prescription for medicati on if the code is determ ined to be a v al id code. The health service may be a pharmacy.

Further, in another embodiment there is provided a test device, the test device comprising:

a test portion adapted to identify at least one biological entit in a biological sample received from a user of the test device,

a first indicia portion configured to indicate the presence or absence of the medical condition based on identification of the at least one biological entity in the biological sam le, and

a second indicia portion configured to display all or part of a code when the first indicia portion provides an i ndication of the presence of the medical condition, the code being substantially unique to the test device.

The device may comprise at least one electronic display, wherein at least the second indicia portion is provided by the at least one electronic display. The first indicia portion and the second indicia portion may be provided by the at least one electronic display. The first and second indicia portions may be provided by different regions of the same electronic display. The code may be a composite code comprising a first code portion and a second code portion, wherein the test device is configured to display at least the first code portio at the second indicia portion, only on or afte providing the indication to the user of the presence or absence of the medical condition. The second code portion may be displayed substantially at all times. The second code portion may be printed, embossed, etched or engraved directly on the test device or a label that is affixed to the test device. The second code portion may correspond to a serial number of the test device. The serial number may be alphanumeric. The device may comprise a printed circuit board, wherein the second code portion corresponds to a serial number of the printed circ uit board. The serial number may be displayed on the printed circuit board in a human or machine-readable form . The printed circuit board may comprise or may be connected to a processor and the processor may be

programmed to cause the electronic display to display the first code portion. The device may be configured to identify a plurality of different biological entities in the biological sample and selectively indicate to the user the presence of one of a plurality of medical conditions, based on identification of one of the plurality of different biological entities. The code that is displayed by the second indicia portion when the first indicia portion provides an indicatio of the presence of the medical condition may be different depending on which of the plurality of medical conditions is present. The plurality of medical conditions may include influenza A and influenza B. Still further in one embodiment there is provided a computer-implemented, processing system comprising:

an electronic user interface adapted to receive a code from a test device, the test devi ce being configured to provi de an indication of the presence or absence of at least one medical condition, based on identification of at least one biological entity in a biological sample received from the user and display all or all or part of the code when the test de vice provides an indication of the presence of the medicai condition, the code being substantially unique to the test device; and

a processor adapted to:

compare the recei ved code to a database of codes to determine if the received code is a valid code; and

instruct dispensing of medication or issuing of a prescription for medication if the code is determined to be a valid code,

B automating the dispensing of the medication, it can be unnecessar for a pharmacist, or indeed any other medicai practitioner, to consider the validity of the code and/or make a subjective determination of the patient's need for the medication . While this can increase the effici ency of the system in general, it can also provide an approach particularly suited for handling dispense of medication on increasingly large scales, e.g. during an epidemic or pandemic. In such situations, there may be insufficient numbers of suitabl qualified pharmacists or medical practitioners to process all persons in need of medication. Despite this, it is recognised that certain aspects, embodiments and features described herein may be adapted such thai they involve persons such as pharmacists or medical practitioners.

In the processing system, providing the instruction may include sending an instruction signal to a dispense module, the dispense module being configured to dispense medication or a prescription for medication upon receipt of the instruction signal. Alternatively, providing the instruction may include sending an. instruction signal to a pharmacy interface configured to instruct a pharmacist to dispense medication or a prescription for medication upon receipt of the instruction signal, instructing a pharmacist to. dispense medication or i ssue a prescription for medicati on may include presenting a direct command to the pharmacist., or providing an indication to the pharmacist that dispense of medication or issuing a prescription for medication would be appropriate or acceptable. The pharmacist interface may include an electronic display and the command or indication may be provided on the display. Dispensing of medication or issuing of a prescription for medication, using the dispense module or otherwise, may include despatching medication or a paper prescription by post, delivering an email containing an electronic prescription or uploading an internet-accessible prescription, or issuing a prescription and/or medication 'over the counter', e.g. ^'within a pharmacy. Where action is taken 'over the counter' or otherwise, a pharmacist may access the pharmac interface of the processing system to receive a command or indication as discussed above, in general, accessing the processing system may allow the pharmacist to determine whether a user of the test device has been previously determined to have supplied a valid code via the user interface, and has not yet received medication or a prescription on the basis of this code. Alternatively, the pharmacist or user may input the code to the user interface, e.g. when the user attends the pharmacy. In this regard, the user interface as well as the pharmacy interface may be accessible within the pharmacy in some embodiments. in addition to the di spensing of medication or i ssuing of prescriptions, the system may generate medical information for the user, a medical certificate for time off work and/or send details to a national health database, such as a National Infections Registry (e.g., in USA, U , Australia and NZ), or otherwise.

The test device may be configured to identify a plurality of different biological entities in the biological sample and selectively indicate to the user the presence of one of a plurality of medical conditions, based on identification of one of the pluralit of different biological entities. The code that is displayed by the test device may be selected from a plurality of different codes depending on which of the plurality of medical conditions is present. In the processing system, therefore, if the received code is determined to be a valid code, the processor may (i) modify the instruction to dispense medication or issue prescription for medication, and/or (ii) modify the generation of medical information for the user, the medical certificate for time off work and or the details sent to a national health database, depending on which one of the plurality of different codes is received. Nonetheless, in addition to or as an alternative to the processor modifying its processes based on different valid codes, it may do so based on details input to the user interface by other means, e.g. through a user typing details of the medical condition into the user interface or selecting one or a plurality of medical conditions presented by the user interface to the user.

In accordance with preceding discussions, the test device may detect the presence or absence of one or more specific biological entities, such as antigens. The antigens may be found in respiratory or blood-borne viruses or infections. Examples include Influenza A (including the H i Nl virus subtype). Influenza B, Respirator Synctial Virus, parainfluenza viruses, adenoviruses, rhinoviruses, coronaviruses, coxsackie viruses, HIV viruses, and/or enteroviruses. The device may be used for the testing of sexually transmitted infections such as gonorrhoea, chlamydia or otherwise. Nonetheless, a wide variety of other medical conditions such as viruses, infections or otherwise may be tested by a test device according to the present disclosure.

The test device may employ principles of iromunochromatography, e.g. as described with respect to preceding aspects, and/or may employ other biological entity test techniques. The test device may include a test zone, which may form part of e.g. a. lateral flow test strip comprised in the test device. The presence of the medical condition and/or the code may be revealed by virtue of a chemical, .reaction or chemical process within the test zone. The test zone may include the first and second indicia portions. When the biological entity is present in the sample, the biological sample may induce a visible change (e.g. a colour change) in the first and second indicia portions. The chemical process may he such that indicia, suc as one or more visible lines, is revealed at the first indicia portion, indicati ve of the medical condition being present, and a code is revealed at the second indicia portion.

As an alternative, or in addition, to utilising a chemical reaction based change to reveal test results and the code to the user, the test device may comprise a reader which provides an electronic indication of the test results a d/or code. The reader may include eleetronic circuitry that identifies indicia at a test zone of the test device that is indicative of the medical condition being present. The electro ic circuitry may comprise at least one printed circuit board (PCB). The indicia may or may not be visible to the human eye, e.g. the indicia may be visible in the colour spectrum or infrared spectrum, for example. Regardless, to the extent that the reader determines that the indicia is indicative of the presence or absence of the biological entity under test, the reader can make a determination about the medical condition and display electronically the results of the test and/or the code to the user as appropriate. In this regard, the test device may include one or more electronic screens and the electronic circuitry may transmit signals to the electronic screen(s). The one or more electronic screens may employ LCD, LED, OLED, Plasma., electroluminescent technology or otherwise. The one or more electronic screens may have a segmented display. The first and second indicia portions may be comprised in a single electronic screen, e.g. as different regions or segments of the same electronic screen, or may be comprised in separate, respective, electronic screens. As indicated, the code may be a composite code comprising a first code portion and a second code portion. The first code portion may be partially or entirely hidden prio to the de vice prov iding to t he user an indication of the presence of the medical condition and the. second code portio may be visible substantially at all times. For example, the second code portion ma be permanently displayed, e.g. by being printed, embossed, etched, or engraved, etc., directly on the test device or a label that is affixed to the test device, and the first code portion may be revealed to the user only upon the test device determining the presence of the medical condition.

Whi le it is recogni sed that rev ealing of all or part o f the code may provide to the user an indication of the presence of the medical condi tion , it is preferable that the test device in this embodiment provides to the user an indication of the presence of the medical condition substantial ly independently of revealing the code. For example, where first and second indicia portions are provided, the first indicia portion may present a plus ("+") sign to indicate the presence of the medical condition, i.e. to indicate a positive test result, or a minus "-") sign to indicate the absence of the medical condition, i.e. to indicate a negative test result. The second indicia portion may display all or part of an alphanumeric, numeric or alphabetic code, for example. By separating the indication of the test result from the displaying of the code, the results of the test may be more easily discernible for the user. Further, the process fo revealing the code need not affect the process for determining the presence or absence of the medical condition, and, accordingly, the accuracy of the test device may be higher. Also, by separating the code from the displaying of the test results, the code feature may be "turned off without rendering the test device ineffective. For example, in situations where the device is to be used to test for the presence or absence of a medical condition only, and not in conjunction with a medication dispense system or other type of validation scheme, electronic circuitry of the test device may be adapted so that it does not reveal a portion of the code to the user upon determining that the medical condition is present.

The test devic e i s con figured to provide an indication of the resu lts of the test directly to the user. This contrasts wi th a system in which the results of the test are only revealed to the user by a health service provider upon receiving and analysing the code, e.g. so that counselling or other advice may be provided to the user immediately. In the present disclosure, since the test device provides the user with the results of the test, the user may have greater impetus to seek medicatio and/or medical attention using the code. Furthermore, this approach may provide less pressure on health service resources, since only those who test positive need seek further engagement.

B permanently displaying a second portion of the code, and initially hiding a first portion of the code, certain advantages may e achieved. For example, the second code portion may correspond to a serial number of the device that is used in tracking of the device during manufacturing, factory testing and/or packaging; etc. The serial number may propagate partially or entirely through the manufacturing process. Since a serial number may be, as a matter of standard practice, substanti al l y unique to a product, the complexity of generating a substantially unique code for validation purposes ma be reduced. Nonetheless, by providing a second portion of the code, which may be considered an "authentication code", for example, which is initially hidden, the complete composite code may be revealed to the user only when a positiv test result is achieved. Further, by employing a serial number as a portion only of a composite code, it is harder for a person, e.g. without access to the test device, to guess the composite code based on analysis of standard serial number formats, etc,

The second code portio may be identical to the serial number. However, the second code portion may be considered to correspond to the serial number even if it is not identical to the serial number. For example, the second code portion may be generated by subjecting the serial number to an algorithm, such that there is direct correlation between the second code portion and the serial number.

Advantageously, the first code portion may tak a relatively short form, while, in combination with the second code portion, it can form a composite code with the required degree of uniqueness and sparseness across the manufacturing volume. When the first code portion is displayed on an electronic screen such as an LCD screen, the screen may therefore be configured to display a relatively low number of characters, potentially reducing screen sizes and manufacturing costs.

While the second code portion may be substantially unique across all test devices, the first code portion may not be substantially unique across ail test devices. However, in combination with the second code portion, which may correspond to the serial number, a substantially unique composite code including the first code portion can be provided, in one embodiment, the second code portion may include at least 1.0 alphanumeric digits and the first code portion may include at least 3 numeric digits. Th length of th second code portion, particularly when cowesponding to the serial number, may be chosen as a trade-off between a user transcribing experience, while allowing sufficient digits to act optionally a identifiers, e.g. 'check' digits, batch f and/or expiry date codes, and product recall numbers, etc. Furthermore, the length can provide sufficient uniqueness and sparseness to allow a substantially unique code, which is difficult to guess, to be realised across the entire manufacturing volume, which may include multiple product lines.

While a full, alphanumeric symbol set may be used in the generation of all or part of the code, e.g. for the second code portion, in some embodiments a reduced set may be used that omits characters that are vulnerable to misidentif cation. For example, since confusion between I and 1, O and 0, Z and 2 and 1 and 7 account for a significant portion of transcribing errors in medical environments, these characters may be omitted from the code. Hie letter U may also be omitted to reduce the chance that vulgar words would appear in the code. Where the code is produced using characters that are employed in languages and' or numeric systems beyond those traditionally used in English speaking countries, other characters may be omitted under similar principles.

The first character of the code may be a fixed identifier. For example, it may be used to identify the type of medical condition under test. For example, "F" may be employed as the lead character indicative of an lnFi.ue.nza test (since "F may not be in the available symbol set). An alphanumer ic character at the end of the code may provide a check digit allowing an immediate determination of whether or not the code is of an appropriate form when entered into the user interface, for example. A standard function may be applied to all of the code symbols to determine if the check digit is viable. One example function is to XOR. However, to avoid generating a check digit that is unavailable a MOD (modulo) function may also be applied.

The processing system may be adapted to include or communicate with a manufacturing system of the test device. The manufacturing system may comprise a line control system (LCS). The processing system may include a central server and/or database that generates and/or records details of each serial number and its associated authentication code.

The processing system may comprise one or more processors and data storage devices. The processors may each comprise one or more processing modules and the storage devices may eac comprise one or mor storage elements. The modules and storage elements may be at one site or distributed across multiple sites and

interconnected by a communications network such as the internet.

The processing modules can be implemented by a computer program or program code comprising program instructions. The computer program instructions can include source code, object code, machine code or any other stored data that is operable to cause a processor to perform the methods described. The computer program can be written in any form of programming language, including compiled or interpreted languages and can be deployed in any form, including as a stand-alone program or as a module, component, subroutine or other unit suitable for use in a computing

environment. The data storage device may include suitable computer readable media such as volatile (e.g. RAM) and/or non-volati le (e.g. ROM. disk) memory or otherwise.

The electronic user interface of the healthcare service may be accessible via e.g., a website interface or application software (e.g. an "app") that is accessible or

downloadable in a personal computing device such as a laptop, smartphone or tablet computer, etc., or accessible by other electronic means. Communication with the user interface may be through a communications network such as the internet or a local intranet or otherwise. The user interface may be configured to receive a variety of different items of information from the user, including the substantially unique code obtained from the test device, and persona! information from the user including one or more of address details, payment details, government or national health service ID numbers, and pre-existing health conditions, etc. Personal information may be inputted by a user each time they access the electronic interface and/or a user may open an. account into which personal information may be entered and recalled for future use.

Similarly, the pharmacy interface may be accessible via e.g., a website interface or application software (e.g. an "app") that is accessible or downloadable in a personal computing device such as a laptop, smartphone or tablet computer, etc., or accessible by other electronic means. Communication with the pharmacy interface may be- through a communications network such as the internet or a local intranet or otherwise. The pharmacy interface may be configured to receive a variety of different items of information from the pharmacist (or their assistant), including their name and pharmacy details, etc. Information may be inputted by a pharmacist each time they access the electronic interface and/or a pharmacist may open an account into which personal information may be entered and recalled for future use.

The system may provide backup options, e.g., if no internet connection is available for the user and/or pharmacist or other health service provider. For example, a telephone user interface may be included, with the user speaking or t ping the code from the test device into a telephone handset. Nonetheless, the option to speak in a code may be "turned off if its users are likely to be vocally impaired, e.g. through having influenza. Similarly, a telephone pharmacy interface may be included which can provide information to the pharmacis about whether or not to dispense medication to the user, etc.

When the code is a composite code, the electronic interface may be adapted to receive input of the composite code as a whole, or maybe adapted to receive e.g., the first and second portions of the composite code separately. In the latter example, user may input one code portion at one data entry point (e.g. in a first "box") and input a second code portion at a different data entry point (e.g. in a second "box").

As indicated, the second code portion, which can form part of a composite code, may correspond to a serial number that is adapted for use in tracking of the device during manufacturing, factory testing and packaging, etc. In one embodiment, the test device comprises a printed circuit board (PCB), with the serial number being provided on the PCB or included with documentation accompanying the PCB. The serial number may therefore be associated with the PCB prior to assembl of the test device. In essence, in some embodiments, the second code portion, used as part of the composite code of the test device, ma be "extracted" from the PCB, during the test device manufacture process. The serial number may be assigned to the PCB during manufacture of the PCB or after its manufacture. The serial number may be assigned to the PCB specifically for use in relation to validation of test results of a test device as disclosed herein and/or it may be a serial number assigned to the PCB for the purposes of identifying and tracking the PCB, etc In addition to or as an alternative to the serial number used in relation to validation of test results, the PCS may comprise one or more other serial numbers for the purposes of identifying and tracking the PCB, etc.

in one aspect, there is provided a method of manufacturing a test device, the test device comprising a test portion for determining the presence or absence of a medical condition., the method comprising:

reading a serial number of a printed circuit board (PCB);

associating an authentication code with the serial number of the PCB;

assembling the PCB into a test device; and

configuring the test device to reveal the authentication code upon determining the presence of a medical condition by the test device.

In another aspect, there is provided a system for manufacturing a test device for determi ning the presence or absence of a medical condition, the system comprising: an electronic reader adap ted to read a serial number of a prin ted circuit board (PCB) or an electronic input device adapted to receive input of a serial number of a PCB; a processor adapted to associate an authentication code with the serial number of the PCB that has been read by the electronic reader or been input into the electronic input device;

an assembly mechanism for assembling the PCB into a test device such that the test device is configured to reveal the authentication code upon determining the presence of a medical condition.

The authentication code may provide a first code portion of a composite code, in accordance with preceding discussions. The device may be configured to displa a second code portion, corresponding to the serial number, and which forms part of a composite code with the first code portion, also in accordance with preceding discussions.

The reader may be a scanning device and the serial number of the PC B may be encoded within a barcode, Q code or RFID tag, or NFC tag, etc. The electronic input device may include a keypad that allows a human to enter the serial number. The serial number may be provided on a label attached to the PCB or on packaging or

documentation that accompanies the PCB.

The serial number when provided with the PCB may be in a machine readable and/or human readable format. Where the serial number is in a machine readable format, the method and system may translate the serial number into a human readable format for display on the test device or on packaging or documentation associated with the test device during the manufacture process. This can allow the user to read the serial number in order to obtain part of the composite code.

Upon reading the serial number, the manufacturing system may be configured to associate the authentication number with the serial number by randomly or pseudo- randoml generating the authentication number, by recalling an authentication number from a list of pre-generated authentication numbers, or through alternative means. Details of the associated serial number and authentication code can be recorded by the manufacturing system and/or other parts of a larger processing system, e.g. when the test device is to be used in a medication dispensing system of the type described in preceding discussions.

Assembling the PCB into a test device may include locating the PCB into a housing of the test device. The test device when assembled may comprise a variety of different components in addition to the PCB and housing, such as one or more lateral flow test strips, biological sample receiving portions, and one or more electronic screens, etc. The test device may include flexible wings, e.g. as described above with respect to preceding aspects. Assembling the PCB into a test device ma also comprise displaying the serial number in a human readable format on the test device or on packaging or documentatio associated with the test device.

in one embodiment, configuring the test device to reveal the authentication code upon determini ng the presence of a medical condition may comprise programming the PCB to cause an electronic display comprised in the test, device to display the authentication code to the user upon determining the presence of a medical condition.

Devices according to the present disclosure may carry advertising, printed on its cover layer and/or backing layer, for example, which advertising may relate to remedies to cure any ailment for which the user may test positive using the device.

In some embodiments, the device may comprise a light source configured to enhance the readability and clarit of test results. The light source may be configured to operate at a precise frequency suitable for enhancing the indicator of a positive and/or negative result at the one or more test zones (e.g. a line or cross, etc.). The light source may comprise one or more light emitting diodes (LEDs), for example.

The light source may provide enhancements in accordance with principles of fluorescence discussed in European Patent Publication No. EP 1582598 A3 , the contents of which are incorporated herein by reference. Accordingly, in a device according to the present invention, a persistent fluorescent structure may be provided in the label-holding zone and the arrangement may be such that the fluorescent structure, which may be one or more quantum dots, for example., can bind at the label-holding zone to the biological entity (target analvte) under test, and can be retained as part of a labelled complex at the test zone. The light source may be configured to emit a wavelength of light suitable for causing fluorescence of the fluorescent structure, causing the structure when present at the test zone to fluoresce and emit fluorescent light at a different wavelength to the light source. In effect, when a target analvte is present in the sample, the indicator at the test zone may fluoresce, increasin the ease at which the indicator can be read, whether visually (e.g., if the fluorescent tight is in the visible wavelength range), or using an additional device such as an electronic reader. A electronic reader may include one or more photodiodes or other photoelectrical, devices. The fluorescence ma increase substantially the effecti ve sensitivity of the device, which may be dictated by the user's ability to observe an indicator at the one or more test zones or the sensiti vity of an electronic reader . in accordance w ith one or more aspects of the present i nvention, however, the l ight source may be configured to backlight the one o more test zones of the testing portion. Accordingly, the light source may not obscure a user's line of sight of the test zones, or a path for the fluorescent light to be transmitted to an electronic reader. To enable backlighting of the test zones, the test portion may be partially or entirely transparent or translucent.

The light source ma be actuatable by way of an actuation mechanism that also releases liquid from the one or more reservoirs that may optionally be comprised in the device, as discussed above. Accordingly, the illumination means may remain off at least until the user releases liquid held in the one or more reservoirs. Additionally or alternatively, the light source may be actuatable automatically upon sensing liquid. For example, the light source may be actuatable automatically upon a liquid sample (e.g. blood or urine) being deposited or transferred to the sampling portio or testing portion and/or upon sensing of liquid from a reservoir, which may be included in the device, at the sampling portion or testing portion. To actuate the light source, the device may comprise an eiectranic circuit that is connected to spaced points of an absorbent part of the sampling and/or testing portion, such that liquid passing through the absorbent part will complete the electronic circuit.

This approach, to illuminating the testing portio to enhance the readability of the test results may be carried out with respect to the device according to any one of the preceding aspects, e.g. a device configured to test for the presence o absence of one or more biological entities in a biological sample, the device including a sampling portion comprising flexible materia! adjustably conformable to a part of a. human or animal body for receiving a biological sample directly from the body; and a test portion in fluid engagement with the sampling portion, the test portion comprising one or more test, zones.

However, in accordance with the sixth aspect of the present invention discussed below, the approach may also be taken with other test devices, which devices ma not comprise a sampling portio that has the same flexibility properties, for example. The approach may be applied to otherwise conventional pregnancy test kits or virus test kits, for example.

According to a sixth aspect, the present invention provides a device configured to test for the presence or absence of one or more biological entities in a biological sample, the device comprising: an at least partially transparent or translucent medium, the medium comprising: a label-holding zone includin a labelling substance configured to bind a fluorescent structure to a biological entity in the biological sample; and

a test zona configured to indicate the presence or absence of one or more biological entities in the sample, and

a light source;

wherein the test zone is readable at a first surface of the medium, and the light source is located adjacent a second surface of the medium, at. a substantially opposing side of the medium to the first surface, such as to backlight the test zone.

The medium may be a planar structure. The medium may be a lateral flow medium. For example, the medium may be a sheet or strip of material. The medium may be a lateral flow test strip, for example.

Brief Description of the Drawings

By way of example only, embodiments are now described with reference to the accompanying drawings, in which;

Fig. 1 shows a plan view of a test layer of a device according to a first embodiment of the present invention;

Fig. 2 shows an exploded view of a device according to the first embodiment of the present invention, comprising the test layer of Fig. 1;

Fig. 3 shows a front plan view of a device according to a second embodiment of the present invention;

Fig. 4 shows a rear plan view of the device of Fig. 3;

Fig. 5 shows an exploded view of a device according to a third embodiment of the present invention;

Fig. 6 shows an exploded view of a device according to a fourth embodiment of the present invention;

Figs. 7a to 7d show steps for using the device of Fig 6;

Fig. 8 shows a schematic oblique, view of a device according to a fifth embodiment of the present invention; Fig, 9a and 9b show opposing side views of the device of Fig. 8, and Fig. 9c shows an end view of the device of Fig. 8;

Fig. 10 shows an exploded view of the device of Fig. 8;

Figs, i la and I l b show bottom and top views respectively of a spine of the device of Fig, 8;

Fig. 12 shows a partial cross-sectional view of the spine of the device of Fig. 8;

Figs 13a to 13c show oblique cross-sectional views of the device of Fig. S with a slider in. different actuation positions;

Fig. 14 shows a schematic plan view of a test strip for use in the device of Fig. 8;

Fig. 15 shows an exploded view of a device according to a sixth embodiment of the present invention;

Fig. 16 shows a schematic side view of a test strip and LED for use in the device of Fig. 15;

Fig. 17 shows a side view of a device according to a seventh embodiment of the present invention;

Figs. 18a to 18c show example display outp uts from the device of Fig. 17;

Fig. 19 shows a serial number label of the device of Fig. 17;

Fig. 20 represents a processing system according to an embodiment of the present invention;

Fi g. 21 shows a webpage that ca be used in the system of Fig. 20; and

Fig. 22 shows software architecture for a processing system according to an embodiment of the present invention. Detailed Description of ¾

A test layer 1 for a device 10 accordin to a first embodiment of the present invention is shown in Fig. I . The test layer .1 is a substantially square, pliable sheet, formed of soft, absorbent padding material. The test layer i is divided into two sections; a sampling portion I i , provided at a central region of the test layer 10; and a testing portion 12, provided to the outer side of the sampling portion 1 1. The testing portion 12 is formed integrally with the sampling portion 1 1 in this embodiment. The sampling portion 1 1 is designed to have a sufficiently large surface area, and to be sufficiently pliable, to extend over a person's nose, permitting the person to deposit nasal mucus on the sampling portion 1 1 , using a standard nose blowing technique.

The testing portion 12 comprises a label -ho I ding zone 13 encircling the boundary between the testing portion 12 and the sampling portion 1 1 and formed of a strip of the testing portion impregnated with a label-holding substance which contains a soluble and labelled antibody specific to a particular antigen. The testing portion 12 further comprises four test zones 14, each provided to the outer side of, and spaced from, the label-holding zone. Each test zone comprises a short thin test line 15, which is a line on the surface of the testing portion impregnated with antibodies or antigens.

In use of the device 1, after a nasal mucus sample is deposited at the sampling portion I I, a buffer solution is dropped onto the mucus sample, using a dropper, increasing its fluidity. The sample spreads out from the deposition point, through the testing layer 1, via capillary action. Upon crossing the boundary between the sampling portion 1 1 and the testing portion 12, depending on the type of antigens present in the sample, the sample can combine with the labelled antibodies at the label-holding zone 13 to form an antigen -antibody (labelled) complex. Upon continued movement through the testing portion, the complex can encounter the test zones 14, causing a colour change along one or more of the test lines 15. The change in colour can thus be indicative of the presence of a specific biological antigen in the sample. By providing foitr different test zones 14, i this embodiment the presence or absence of at least four different biological antigens may be detected.

With reference to Fig. 2, in addition to the test layer I, the device 10 comprises a cover layer 2 and a backing layer 3. The cover layer 2 is a transparent, flexible film of fluid-resistant plastic material attached to a front side of the test layer L The cover layer 2 extends to the outer edges of the testing layer 1, but a hole 21 is provided at the centre of the cover layer 2, aligned with the sampling portion 1 1 of the test. layer 1. Accordingly, a fluid sample can be recei ved by the sampling portio 1 1 through the hole 21 in the cover layer 2. The cover layer 2, and hole 21 thereof, are arranged to serve as a guide, indicating where the fluid sample should be deposited, and the cover layer is also arranged to act as a barrier to prevent direct application of the fluid sample, and/or other fluids or environmental substances, to the test portion 12, which might adversely affect test results. Furthermore, the cover layer 2 can prevent leakage of the fluid sample through the front of the test layer 1. Since the cover layer 2 is transparent, the reactions at the test zones 14 can be observed through the cover layer. The backing layer 3 is attached to the rear side of the test layer 1 and extends to the outer edges of the test layer 1. The backing layer 3 comprises flexible, fluid- resistant material, which prevents leakage of the fluid sample through the rear of the device, e.g., onto a hand or other surface. The material of the backing layer 3 is preferably slide resistant material to allow easier gripping of the device by a user, and to facilitate gripping of the device onto a surface (e.g. a table or bench top), whilst the reaction of the one or more test zones 14 is observed.

A de vice 101 according to a second embodiment of the invention is shown in Figs. 3 and 4. The device 101 is similar to the device 10 of the first embodiment. However, the cover layer of the device 101 does not extend to the edges of the test layer ί '. Rather, it stops short of the edges of the test layer 1 leaving art outer region of the front surface of the test layer 1 ' exposed, hi this embodiment, the exposed outer region of the test layer 1 ' is a absorbent strip of materia! 16. The absorbent strip 16 is formed of a different material to the remainder of the test layer Particularly, the material of the absorbent strip 16 is more absorbent than the remainder of the test layer 1 Accordingly, the absorbent strip 36 can prevent fluid from spilling out of the edges of the test layer 1 ' onto a user's hands or the floor etc.

Furthermore, the device 101 comprises two fixation devices, in particular two adhesive pads 17, located proximate two adjacent corners of the test layer V. The adhesive pads 17 are arranged to stick, upo folding of the device 1.01 in half, to locations prox imate the other two comers of the test layer 1 '. To help a user fold the device in half, dotted fold line 22 is printed down the centre of the cover layer 2 In alternative embodiments, a cut or channel may also be provided in one or more of the layers of the device 101 to assist folding. The device 101 is arranged to be folded after deposition of a sample on the sampling portion 1 1 such that the sample is no longer visible. Instead, only the backing layer 3' will generally be visible after folding.

Following on from this, wi th reference to Fig. 4, observation of test results using the device 10 ! can be made through the backing layer 3¹ in this embodiment. Particularly, the backing layer 3^* comprises windows 3 1 through which the reaction of the test zones can be observed. More particularly, the backing l ayer 3 ' comprises four sets of two windows 3 1, the two windows of each set allowing observation of a positive or negative indication at each test zone for die presence of various virus antigens in the sample under test. In this embodiment markings are printed on the backing layer 3' to indicate different types of viruse that are under test. Other markings such as brief rastractions 23 and guidance on. interpretation of results and/or a direction to refer to an instruction book, a handbook and/or an associated website, can also be provided on the backing layer 3 ' .

A device 102 according to a third embodiment is shown in Fig. 5. in this embodiment the test layer is made up of two separate layers, a sampling layer l a, which is a substantially circular pad that is arranged to locate underneath a central hole 21 in the cover layer 2", and a test strip layer lb, which has a central substantially circular section 18 that is arranged to locate underneath both the hole 21 and the sampling layer la, and also has four arms 19 projecting radially from the central section 18. The sampling layer l a in combination with the central section 18 of the test strip layer l b provide at least part of a sampling portion for the device 102, for receiving a sample from a patient through the hole 21 in the cover layer 2", and the arms 19 of the test strip layer lb provide at least part of a test portion for the device 102.

At the transition between the central section 18 and the arms 19 of the test strip layer lb, a label-holding zone is provided which is configured substantially as described above with respect to previous embodiments. The testing layer 1 b further comprises a plurality of test zones 1.4, each provided on one of the arm 19 extending from the central section 18. The test zones 14 are also configured substantially as described with respect to previous embodiments. By providing four different test zones 14 in this embodiment the presence or absence of at least four different biological antigens may be detected.

The device 102 also comprises a sealed reservoir of buffer solution, taking the form of a substantially circular, low profile capsule 4 in this embodiment The capsule 4 is provided underneath the sampling layer la and the centra! section of the test strip layer 1 b. A backing layer 3" is also provided to the underside of the test layer, but which has a central substantially circular window 32 in which the capsule 4 can locate. The capsule 4 is provided across a central fold line 22 of the device.

A device 1 3 according to a fourth embodiment is shown in Fig. 6. The device is substantially the same as the device of Fig. 5. However, the test-strip layer lb' has been, effectively, cut in half. In this regard, it comprises a substantially semi-circular central section 18' and comprises only two arms 1 ', allowing determination of the presence or absence of two different biological entities. The central section 1.8' and aims 1.9' are provided to one side only of the fold line 22 of the device. Accordingly, the central section does not interfere with folding of the device, and observation of the test results on one half only of the backing layer need be made, when the device is used in a manner described below. With, reference to Figs. 7a to 7d, a method of using the device of Figs. 5 or 6 is shown (although the device 1.03 of Fig. 6 only is represented in Figs. 7a to 7d). Each device 102, 103 is configured so that a person can blow their nose on the device 102, 103 to apply nasal discharge to the sampling portion via the hole 21 in the cover layer 2" (Fig. 7a). The device 1 2, 103 can the be folded in half along line 22, generally in a manner as described above with, respect to the second embodiment, so that only the backing layer 3" and the capsule 4 are visible (Fig. 7b). During folding of the device, the capsule 4 is also folded, and becomes located at an edge of the folded device. The user (e.g., the person undergoing testing) can then press firmly on the capsule 4, which is exposed through the hole 32 in the backing layer 3", causing the capsule 4 to break (Fig. 7c). By breaking the capsule 4, buffer solution is released from the capsule 4, which spreads through the sampling portion and mixes with the deposited nasal discharge sample, resulting in a fluidic sample solution. The sample solution may then fluidicafly transfer from the sampling portion through the label-holding zone to the test zones 14 of the arms 1 to provide a test reading visible through windows 3 1 in the backing layer 3" (see Fig. 7d), generally in a manner set out with respect to the second embodiment, By providing a device 102, 103 with an integral capsule 4, the device 102, 103 may be easier to use. The device 102,, 1.03 may allow testing to be performed without requiring any additional solutions being applied or additional apparatus to be used.

Each device 102, 103 of the third and fourth embodiments carries instructions 23 on its cover layer ' and backing layer 3". The instructions are located at

appropriate posi tions of the device so that the are visible when they are to be carried out Furthermore, the device carries advertising 24, which advertising may relate to remedies to cure any ailment for which the user may test positive using the device.

In the various embodiments, the resul ts of the testing may be indicated at the test zones by the revealing of an indicator such as for a positive test and a for a negative test or otherwise. Additionally or alternatively, where a test is positive, a unique code or identifier (not shown) may be revealed,

With reference to Figs. 8 to 14, a device 200 according to a fifth embodiment of the present invention is now described. The device 200 may be considered to take, generally, a butterfly shape, due to the inclusion in the device of two wings 201 , 202, provided by two substantially flat and flexible sampling elements, and a spine 203, provided by an elongate central body, the wings 201 , 202 extending from, and being relatively pivotable about, the spine 203, The wings 201 , 202 are designed to have a sufficiently large surface area, and to be sufficiently pliable, to flex around a person's nose 204, permitting the person to deposit a nasal mucus sample in a region between the two wings 201, 202, using a nose blowing technique. A simplified drawing of the device 200, with the wings 201. 202 in an open configuration, showing how the device 200 may be brought into a position with a nose 204, is provided in Fig. 8. A more detailed drawing of the device 200, with wings 201 , 202 in a closed position, e.g., prior to use of the device, or after receipt of tire sample, is shown in Figs. 9a to 9c. As can be seen in these Figures, on. the outside of each wing 201, 202, a respective finger locator is provided. Each finger locater includes a pad 205 with a hole 206, for receiving a finger or thumb tip 207. By placing the tips 207 of their thumb and forefinger (or other fingers) in the hole 206 of each locator, the user will generally position the device 200 correctly when it is brought into contact with their nose 204 for nose blowing, so that a nasal sample is received at a targeted location of the device 200. Although this device 200 is configured to obtain and test nasal discharge, in alternative embodiments, the device may be configured to obtain and test other biological samples, such as blood, serum, plasma, saliva, sputum, urine, ocular fluid, tears, semen, vaginal discharge, ear secretions, perspiration, mucus, stool, and/or amniotic, spina!, wound, or abscess fluid.

Figure 10 shows an exploded view of the device 200, allowing the various components of the device 200 to be seen in more detail. The two wings 201 , 202 are formed from a waterproof backing layer 208 and respective first and second inner layers 209, 210. The backing layer 208 may be formed of plastic, e.g. a polyester sheet. The backing layer 208 is configured to be folded at a central fold region 2.1 1 along three fold lines 212, which region 211 , when folded, is sandwiched between a top plate 213 and a main body 214 of the spine 203 (see Fig, 9c, for example). The first and second inner layers 209, 210 are mounted on the inner surface of the backing layer 208 at respective sides of the fold region 211. Between the first inner layer 209 and the backing layer 208, an absorbent sample pad 215 is provided. The sample pad 235 provides a lateral flow medium (capillary membrane) and is substantially flexible and absorbent, in this embodiment, the sample pad.21.5 comprises a substantially v-shaped portion 21 and tongue portion 217 extending from one end of t he v-shaped portion 216. At the apex of the v-shaped portion 216, the sample pad 215 comprises a target portion 218, which target portion 218 is substantially oval-shaped in this embodiment.

The first inner layer 209 includes a hole 219 which is slightly smaller than, and located directly over, the target portion 218. The arrangement is such that, with the device 200 correctly located with respect to the nose of a user, through appropriate use of the finger locaters, when the us er depos its a nasal s ampl e between the wings 201 , 202, the nasal sample may pass through the hole 219 and contact the target portion 218. Notably, even if the user were to deposit the sample on the second inner layer 210 of the wing 202 only, by virtue of closing the wings 201, 202 together, the sample may, nevertheless, contact the target portion 218, To ensure that the sample may contact the only the target portion 218 immediatel after deposition, and not other elements of the device underneath the inner layers 209, 210, the inner layers 209. 210 may be formed of substantially fluid-resistant material. In combination with the sample pad 215, the fust and second inner layers 209, 21 and backing layer 208 may be considered to provide a flexible sampling portion, the sample pad 215 providing an absorbent portion of the sampling portion.

First and second lateral flow test strips 220, 221 are mounted on the backing layer 208 suc as to be in fluid engagement with the sample pad 215. Once deposited on the target portion 218 of the sample pad 215, the device is configured such that the sample is transferrable by capillary action., from the target portion 218 via a first arm 216a. of the v-shaped portion 216, to a first end of each lateral flow test strip 220, 221 adjacent a head end 200a of the device 200. In this embodiment, the lateral flow test strips 220, 221 are conventional test strips, although other test strips or testing means applying the principles of immunochromatography or otherwise may be ut lised in this or alternative embodiments. The first and second test strips 220, 221 may be considered to provide a test portion of the device 200.

Referring to Fig. 14, each test strip 220, 221 can include several zones that are arranged sequentially along the length of the strip, including a sample receiving zone 220a, a label-holding zone 220b, a test zone 220c, and a sink 220d. The zones may comprise chemically treated material such as chemically treated nitrocellulose, located on a waterproof substrate. The design is such that the fluid sample, when transferred from the sample pad 215 can continue to travel under capillary⁷ action through the sample receiving zone 220a, into the label-holding zone 220b, which contains a substance for labelling of a target analyte, and into the test zone 220c where the sample will contact a test region or stripe 220e containing an immobilized compound capable of specifically binding the labelled target analyte or a complex that the analyte and labelling substance fonn, The presence of the labelled analyte in the sample generally results in a visually detectable colouring of the stripe 220e.

In addition to the test strip 220e, a control stripe 220f in the test zone 220 can be provided to indicate that a testing procedure has been performed. The control stripe 22 Of can be located downstream of the test stripe 220e and is operable to bind and retain the labelling substance. Visible colouring of the control stripe 220f indicates the presence of the labelt i ng substance resulting from the fluid sample fl owing through test zone 220c. When the target aiialyte is not present in the sample, the test stripe 220e shows no visible colouring, but the accumulation of the label in control stripe 220f indicates that the sample has flown through test zone 220c. Tire sink (absorbent) zone 22 Od can then capture any excess sample, this embodiment, the sample pad 215 is directly connected to the sample receiving zone 220a of each strip 220, 221. However, in other embodiments, the sample receiving zone 220a may be omitted and the sample pad 218 may be configured to fiddly connect directly to the label-holding zone.

The test strips 220, 221 are arranged with their elongation directions configured substantially parallel to the fold lines 212, such that the strips can be enclosed by the elongate body of the spine 203 when the backing layer 208 is folded along the fold lines 212. By enclosing the test strips 220, 221 in the spine 203, the strips, which can be relatively rigid and/or brittle in comparison to the sampling portion, may be prevented from breaking. So that the user can see the control and capture lines 220e, 220f of the strips 220, 2.2 J when the fold region 212 is enclosed by the spine 203, a window 222 is provided in the backing laye 208, and two windows 223, one for each test strip, are provided in the top plate 213. In this embodiment, the two test strips 220, 221 are configured to test for the presence of the influenza A and influenza B virus in the sample. However, in the present embodiment or other embodiments, testing for the presence of one of these vi ruses only, or testing of additional or alternative biologi cal entities, is possible. The device 200 may be modified to include only one test strip, or to include more than two test strips.

The first and second test strips 220, 221 are located in a staggered arrangement in particular, relative to the second test strip 221 , the first test strip 220, which is located nearer to the sample portion 2.15 than the second test strip 221, is located inwardly from the edge of the backing layer 208 at the head end 200a of the device 200. The particular configuration is intended to ensure that the lengths of the fluid engagement paths between the target portion 218 and the first and second test strips 220, 221 is substantially the same. Accordingly, during testing, sample can be expected to reach corresponding locations of the two strips 220, 221 at substantially the same time such that the results of testing indicated by the two test strips 220, 221 may be presented initially at substantially the same time. To bridge the additional gap between the first ami 2 6a and the first test strip 220, an inwardly extending projection 224 of the sample pad 215 is provided.

To assist, in the transfer of the sample from the target, portion 218 to the test strips 2201 , 221. a liquid, e.g., a buffer solution, is provided in the device 200.

initially, the liquid is sealed within a first reservoir. With reference to Fig. ! la, for example, the first reservoir is formed between a blister element 225 and a recess 227 in the bottom wal l 226 of the main body 214 of the spine 203. The blister element 225 may be formed of Aclar^lJVVpolypropylene laminate, for example, and may be attached to bottom wall 226 of the main body via an adhesive. The first reservoir is arranged to hold the liquid underneath a second reservoir of the device 200, the second reservoir being empty of the liquid prior to use of the device 200. W ith reference to Figs 10 and 1 lb, for example, the second reservoir is formed from a substantially rectangula trough 228 at the top side of the main body 214 and a foil element 229 that seals the top of the trough 228.

In the bottom wall 226 of the main body 214, directly between the first and second reservoirs, an opening 230 is provided. The opening 230 is initially sealed by a pierceable film 231. The pierceable film 231 and opening 230 are designed such that, once the film 23 J is pierced, liquid may travel from the first reservoir into the second reservoir. The tongue 21 7 of the sample pad 215 is configured to extend into the trough 228 of the second reservoir. Accordingly, when the liquid travels into the second resenOir, the liquid can be absorbed, ove a period of time, by the tongue 217, whereupon the liquid will travel along the second arm 21 b of the sam le page 215 to the target portion 218 and combine with the deposited sample. The combined sample and fluid will then travel along the first arm 216a of the sample pad 215 to the test strips 220, 221..

To pierce the film 231, an actuation mechanism is provided. The actuation element is intended to be operated after a sample has been deposited and the wings 201 , 202 have been closed together. The actuation mechanism includes a slider 232, siidable along the elongation direction of the spine 203, and a piercing element 233, the piercing element projecting over the hole 230, adjacent the pierceable film 231. The slider 232 has a main body section 234, which is configured to partially surround the spine 203, and a flexible inner flange 235 extending from an inner surface of the main body section 234. The inner flange 235 has a projection 236 at its distal end, the projection 236 being biased by the flange 235 to press against the bottom wall 226 of the spine 203. The spine 203 ma be considered to provide a track for controlled movement of the slider 232.

The operation of the actuation mechanism is now described in more detail with reference to Figs. 12 and 13a to 13c. Referring to Figs, 12 and 1.3a, prior to use, the slider 232 is positioned adjacent the tail end 200b of the device 200, with the projection 236 located in a first recess 237 i the bottom wall 226 of the main body 214 such as to prevent the slider 232 from moving freely relative to the spine 203. However, through the user pushing the slider 232 in the elongation direction of the spine 203, in a direction towards the head end 200a of the device, as indicated by arrow Al, the projection can be forced out of the recess 237, allowing the slider to move towards the blister element 225 of the first reservoir. The configuration of engagement surfaces between the projection 236 and recess 237, however, is such as to prevent the slider 232 from being moved in the opposite direction to directio A l .

With reference to Fig. 1 b, once the slider 232 reaches the blister element 225, the projection 236 presses against the blister element 225, which element 225 in turn presses against the piercing element 233, forcing a sharp end 238 of the piercing element 233 against the pierceable film 231, causing the film 231 to break. The piercing element 233 is located towards the tail end of the first reservoir, and is therefore actuated almost immediately upon the contact between the projection 236 and the blister element 225. As the slider 232 continues to move in the same direction A I, the projection 236 effectively inverts the blister element 225 towards the bottom of the recess 227, forcing liquid from the first reservoir into the trough 228 of the second reservoir, via the opening 230 (the inversion is not represented in Fig. 13b). Once the film is broken, to ensure that the liquid is not prevented from moving towards the opening 230 by opposing movement of the projection 236 across the blister element 225, which might otherwise invoke a seal between the inverted blister element 225 and the bottom of the recess 227, one or more fluid channels 239 are provided in the bottom surface of the recess 227. The channels 239 ensure that the solution can travel underneath the projection and inverted blister element 225, towards the opening 230.

With reference to Fig. 13c, once the slider 232 passes over the blister element

225 , the slider 232 is arranged take up a rest position adjacent the head end 200a of the device 200. To maintain die slider 232 in this position, preventing it from moving freely relatively to the spine 203, the projection 236 is arranged to seat in a second recess 240 and the head end of the slider 200 is arranged to abut a stop element 241 at the head end of the spine 203 such that the slider 232 is prevented from sli ding off the spine 203. The configuration of engagement surfaces between the projection 236 and recess 240 is such as to prevent the slider 232 .from being returned to the tail end 20Gb of the device 200. Accordingly, since the slider 232 will be maintained at the head end 200a of the device, it can remai n immediately apparent to the user that the device 200 has been used, reducing the likelihood of an attempted re-use of the device 200.

With reference to Figs. 15 and 1 , a device 300 according to a sixth embodiment of the presen t i nvention is now described. Similar to the device 200 of the previous embodiment, the device 300 has a spine formed from a top plate 301 and a main body 302, a sample pad 303 located on a backing layer 304 of a pair of wings (not shown), two lateral flow test strips 305, 306, and a slider 307 for actuating release of a liquid, e.g. buffer solution, to assist in .flow of a sample from the sample pad 303 to the test strips 305, 306. On the whole, the configuration and principles of operation of the device 300 are substantially identical to those of the device 200, except for the provision of a mechanism for enhancing the readability of the results of the testing at test zones 305 of the test strips 305 , 306. In pa rticular, to enhance readability, in this embodiment a fluorescent material is provided at the label-holding zone 305b of each of the test strips 305, 306 and one or more LEDs 308 (light emitting diodes) are provided to illuminate the fluorescent material when presented at the test zone 305c of each test strip 305, 306. The arrangement is such that the fluorescent material, which may be one o more quantum dots, for example, can be bound to the biological entity under test (target anal yte) at the label-holding zone 305b of the test strip 305, and can be retained as part of a labelled complex at the test stripe 305e and/or control stripe 305f of the test zone 305 c. The LEDs are configured to emit a wavelength of light suitable for causing fluorescence of the quantum dots, e.g. blue to ultraviolet li ght. The fluorescent light produced by the quantum dots will be optionally of a visible frequency and thus can provide an enhanced, more clearly visible, line at both the test stripe 305e and control stripe 305f when a particular biological entity is present in the sample. Nonetheless, in alternative embodiments, the fluorescent light may or may not be visible to the naked eye, and an electronic reader may be used to sense the presence or level of fluorescent light. The electronic reader may be integrated into the device and the results of the testing may be displayed electronically, for example.

In this embodiment, the LEDs 308 are positioned to backlight the test strips 305, 306. I this regard, the LEDs 308 are located on the opposite side of the test strips 305, 306 to the stripes 305e, 305f of the test zone 305c, The positioning of one of the LEDs 308 relative to one of the test strips 305 is represented schematically in Fig. 1 . The test strip 305 includes a sample receiving zone 305a, a label-holding zone 305b, a test zone 305c, and a sink 305d, which are mounted on a waterproof substrate 305g. The LED 308 is located to the side of the test strip having the substrate 305g, such that light 305h from the LED is directly incident on the substrate, and particularly underneath the test zone 305c of the substrate. The substrate and test zone are at least partially translucent such that the light 305h from, the LED will fall on the stripes 305e, 305f at the test zone and initiate fluorescing of a fluorescent structure located at the stripes 305e, 305f. The fluorescent light 305i may he observed by the user's eye 305j.

This backlighting approach ensures that the LEDs 308 and accompanying electronic- componentry will not obscure the user's view of the test zone 305c and allows the LEDs and electronic componentry to be located in the spine 301. In this embodiment, four LEDs 308 are mounted on one side of a circuit board 309 i additi on to a conductive lever element, providing an LED switch 310, A battery 31 3 is located on the opposite side of the circuit board 309, directly below a slot 312 in the circuit hoard, the slot 312 providing an access opening for the switch 310 to contact the battery 31 1 in order to complete an electrical circuit to supply energy to illuminate the LEDs 308. The switch 310 is resiliently biased from contact with the batter 31 1. However, the device 300 is configured such that, after the slider 303 has moved along the spine to actuate release of the liquid in a reservoir, substantially as described with respect to the previous embodiment, it will reach a rest position whereupon a projection 313 on an inner surface of the slider 303 will extend through a slot 314 in the top plate 301 of the spine and press against the switch 310 to complete the electric circuit.

With reference to Fig 17, a device 400 according to a further embodiment of the present invention is now described. Similar to the devices 200, 300 of preceding embodiments, the device 400 has a housing 401, a pair of wings 402 adapted to receive a biological sample, and a slider 403 for actuating release of a liquid, e.g. buffer solution, to assist in flow of biological sample to test strips located within the housing. The configuration and principles of operation of the device 300 can be substantially identical or similar to those of the devices 200, 300 described previously. However, the device is adapted to include printed circuit board (PCB), an electronic reader to determine test results and an electronic screen 410 that is connected to the electronic reader and that can display information about the test results to the user, along with at least a portion of a code associated with the results. The code can be used in a

validation system that is described in more detail below. While this arrangement, in which a code is produced, is shown in relation to a device having wings similar to preceding embodiments, it may be applied to any test device that is used to indicate the presence or absence of a medical condition, upon receipt of a biological sample from a user.

The electronic reader comprises one or more photodetectors adapted to detect changes in light intensity at stripes of the test zones of one or more test strips enclosed within the housing. Depending on the change in intensity, the electronic reader can determine whether a biological entity is sufficiently present in the biological sample to indicate that the user has a particular medical condition.

in this embodiment, two test strips are enclosed in the housing 401 that are configured to test for the presence of influenza A and influenza B virus in the biological sample, respectively. Nonetheless, in alternative embodiments, a single test strip or more than two test strips may be used. The test device may be configured to test for a variety of different biological entities.

With reference to Fig. 18a, if levels of influenza A and B viruses determined to be present in the biological sample are below respective threshold levels, the circuitry is configured to cause the screen 410 to display a minus sign ("-") 41 la and the letters "A" and "B" 4.12a, 41.2b in a first portion of the screen 4.10, indicating to the user that the test is negative for both influenza types.

With reference to Fig. 18b, if the level of influenza A vims, but not influenza B vims determined to be present in the biological sample is above the respective threshold level, the circuitry is configured to cause the screen 410 to display a plus sign ("+") 41 l b and the letter "A" 412a in the first portion of the screen 430, indicating to the user that the test is positive for influenza A only.

With reference to Fig. 1.8c, if the level of influenza B vims but not influenza A virus determined to be present in the biological sample is above the respective threshold level, the circuitry' is configured to cause the screen 410 to display a plus sign ("+") 41 lb and the letter "B" 412b in one the first portion of the screen 410, indicating to the user that the test is positive for influenza B only.

Where the test results are positive for either influenza A or influenza B, the circuitry is also configured to cause the screen 410 to display a three digit numeric code 413 at a second portion of the screen 410, which provides a first code portion and is referred to hereinafter as an authentication code, in this example, the authentication code is "418". In an alternative embodiment, however, the test device may be configured to display a different authentication code depending on whether influenza A or influenza B is detected, in this alternative approach, the explicit on-screen, indication of "A" or may or may not be provided.

As shown in Figs. 17 and 19, the test device comprises a label 420 that is affixed to the housing 401. A serial number 421 , which is a 10 digit alphanumeric code in this example, and which provides a second code portion, is printed on the label 420, along with a lot number 422 and an expiry date 423 for the test device, in this example, the serial number is "FB24B4MH8P" The serial number has been generated such that it omits characters that are prone to transcribing errors n medical environments. While the label 420 is located on the housing in this embodiment, in alternative embodiments it may be located on the wings 401 or elsewhere on the test device, or on

documentation or packaging accompanying. the test device. Alternatively, one or more of the details on the label may instead be provided directly on the test device, e.g. through printing, embossing, etching or engraving, etc,

In combination, the authentication code and the serial number provide first and second portions of a composite code that can be used by a pharmacy to determine the validit of a request for medication, based on the results of the testing. In this regard, the test device can provide one part of a medication dispense system,

With reference to Fig. 20 a medication dispense system according to one embodiment comprises a plural ity of test dev ices 400, each test device 400 being configured to display a different composite code to the respective user upon providing a positive test result. The dispense system further includes an electronic processing system 450, which includes one or more processors and/or processing modules 451 and one or more storage devices and/or storage modules 452, 453, 454 which devices and modules may be located at the same site, e.g. within a pharmacy building or office or elsewhere, or at different sites and connected via a communications network. Basic features of the processing system are represented in Fig. 20. However, the processing system may have a variety of components and be configured to control other features such as ma ufacturing processes. Software architecture for an expanded processing system in accordance with one embodiment of the present disclosure is discussed further below with reference to Fig. 22,

Referring again to Fig. 20, the processing system 450 is configured to receive information from a user of a test device 400 by virtue of an electronic user interface that is accessible via a website or other software interface accessible through a personal computing device such as a desktop computer 431, laptop computer, tablet computer, or smartphone 432, etc, and which is connected to the processing system 450 via a communications network such as the internet 441 ,

An example website page 460, which includes three boxes 461 , 462, 463 into which the serial number, authentication code, and influenza type can be inputted, respectively, is shown in Fig, 2 ί .

Referring to Fig. 20, i addition or as an alternative to a user interface in the form of a web or software interface, the processing system can be configured to receive information from a user via a telephone 433 which is connected to the processing system 450 via a public switched telephone network (PSTN) 442 or an internet/VoIP network if av ailable.

Along with the composite code, the information received from the user via the user interface can include personal details such as address details, payment details, government or national health service ID numbers, and information on pre-existing health conditions, etc. The details may be inputted by the user in response to a series of questions. Personal details may be inputted by a user each time they access the website or telephone interface and/or a user may open an account into which personal details are entered and recalled for future use. Users' personal details can be stored in a user database 452,

Once the code and any other required information is received from the user, the processing system 450 is configured to compare the code to a database of valid codes 453, to determine if the code is a valid code indicative of the result of a positive test. The comparison may determine if a code has been used before, for example, in which case the code ma be considered invalid regardless of whether or not it was obtained on the basis of a posi tive test. If the code is determined to be a val id code, appropriate medication or prescription information related to the treatment of the medical condition can be accessed from an information database 454.

If, in an alternative embodiment, test devices used with the system are

configured to display a different authentication code depending on whether influenza A or influenza B is detected, the website page 460 may be modified to include no box 462 to receive influenza type information. In this alternative approach, the processing system 450 may determine which influenza type is present based on information in its databases about, the influenza type associated with the particular authentication code that has been provided. Once the code is validated, the processing system 450 is then configured to coordinate or enable the despatch of medication or delivery of a prescription in order to treat the medical condition under test. An example of medication that may be appropriate for the. treatment of influenza includes the antiviral drug Oseltaraivir (TamifliiTM).

The processing system 450 can provide an instruction signal to a dispense module 461 , the dispense module being configured to dispense medication or a prescription for medication upon receipt of the instruction signal.

Alternatively, the processing system can send an instruction signal, e.g. over the internet, to a pharmacy interface 462 configured to instruct a pharmacist to dispense medication or a prescription for medication upon receipt of the instruction signal. Instructing a pharmacist to dispense medication or issue a prescription for medicatio can include presenting a direct command to the pharmacist, or providing an indication to the pharmacist that dispense of medication or issuing a prescription for medication would be appropriate or acceptable.

Thus, when the dispense module 4 1 is employed, delivery of the prescription may take place automatically through a postal service or via electronic means such as deli very of an email or the uploading of an internet-accessible voucher. Alternatively or additionally, a more traditional approach to medication dispense may be available through use of the pharmacy interface 462. A pharmacist may acces the pharmacy interface 462 to obtain information, regardi ng whether or not a user of the test device presenting themselves to the pharmacist has been determined to have supplied a valid code via the electronic interface, and the code has not been used already to dispense medication or a prescription.

Upon determining mat an. appropriate, valid code has been provided, the processing system 450 is also configured to generate medical mforrnation for the user, a medical certificate for time off work and/or send details to a national health database, such as a National Infections Registry 463.

In the present embodiment, it can be unnecessary for a pharmacist, or indeed any other medical practitioner, to consider the validity of the code and/or make a subjective determination of the patient's need for medication, prior to the medication being dispensed. While this can increase the efliciency of the system in general, it also provides an approach particularly suited for handling the distribution of medicatio on increasingly large scales, e.g. during an epidemic or pandemic. In such situations, there may be insufficient numbers of suitably qualified pharmacists or medical practitioners to process all persons in need of medication through more standard processes.

In this embodiment, the serial number, which is displayed on the test device, corresponds to a serial nu mber that propagates through the manufacturing of the test device. This is now discussed in more detail with reference to Fig. 22, which shows software architecture for a processing system according to an embodiment of the present invention . As can be seen, the processing system described above wit respect to Fig. 22 can expanded e.g. to control manufacturing processes for PCB and test device assembly, etc.

The serial number is associated with the printed circuit board ( PCB) prior to assembly of the test device. The serial number is included in a barcode located on the PCB. This barcode can be scanned at a variety of steps in the manufacturing, test and assembly process for the test device.

As part of PCB assembly 510, the barcode is scanned immediatel prior to a programming and/or a functionality test of the PCB and the randomised authentication code is generated and recorded to a .manufacturing or factory line control system (LCS) that is connected to a centra! server 520 of the processing system . Programming of the PCB can be such that the PCB wi l l cause an electronic screen of the test device to display the authentication code upon a positive test result being achieved.

When the PCB is to be included into the housing (chassis) of the test device as part of product assembly, the PCB barcode is again scanned, if the LCS has indicated that this PCB had passed all the production tests, the serial number present on the PCB code is read and printed onto a product label and is ultimately applied to the assembled test device.

The LCS ensures that a product label can never be printed for a PCB that has not been fully tested or processed (e.g. if a process step has been omitted, the LCS can refuse to print the product label). For more effective onward traceabillty, and so that it can be used in conjunction with code validation, the product label can contain the serial number in both human-readable and machine readable (barcode) formats.

In some embodiments, after the PCB is assembled into the test device, there can be further (product level) tests, and the product barcode label can be scanned. If the test fails, the serial number in question can be quarantined until the product is either repaired or scrapped. If it is scrapped, the LCS can communicate the fact that the serial number is now invalid to the central server, and it can be removed from the database of valid codes.

The product label barcode can also be scanned again prior to packing, in order to print the same serial number information on outer packaging (either via a label, or directly onto a carton using industrial printing technology). Again, if the serial number is invalid, e.g. because tests have failed, it is quarantined or scrapped by the central server. The LCS can refuse to print the label/carton, and thus shipping of a defective product can be avoided.

The above-described manufacturing arrangement employs a single serial number tor the PCS and the fi l test device product (and packaging), which c n be particularly suitable where the PCB assembler and product assembler are part of the same organisation, or in different organisations that are bot capable of accessing the same central server or "back end control system". Nevertheless, if the PCB assembler is not connected to the central server, the generation and communication to the central server of the authentication code may be performed during the product assembly stage. This has the benefit that only the product assembler needs access the serial number database, and may improve testing quality.

If it is not possible to use the same serial number for the PCB and the fin al test device product, a serial number of the PCB ma be replaced, in effect, during the product assembly. During the product assembly, both the serial number and the authentication cod can be generated and recorded substantially at the same time. A PCB barcode label (containing the assembler's preferred serial number, used subsequently for validation coding purposes) can be printed o a label and applied to the PCB (e.g. over the top of an existing label to avoid confusion). This new barcode label can be used by the LCS to track the PCB through the rest of the assembly process, and the association between the old PCB serial number and the product serial number need exist only in the product assembler's LCS.

With reference again to Fig. 22, the central server 520 controls a significant portion of the information processing associated with the dispense system. The central server 520 can store information relating to test device products, including the serial numbers, authentication codes, batch numbers and expiry dates, etc. The central server 520 can also control the issuance of medication/prescriptions, sick notes and medical information. The central server 520 can also connect with one or more national disease registries to enable tracking and monitoring of illnesses. The central server can also perform a comparison of codes received from users of the test device with those in its database for validation purposes, and store information about codes that have been used already.

By using a centra! server, multiple pharmacies 540 and users 560 may be able to access relevant resources in order to participate in the system via respecti ve interfaces, A backup phone based system 550 may also be employed. The central server may access a national register of approved pharmacies to ensure that the only approved, pharmacists participate.

It will be appreciated by persons skilled in the art that numerous varia tions and pr modifications may be made to the invention as shown in the specific

embodiments without departing from the scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims

CLAIMS:

1. A test device, the test device comprising:

a test portion adapted to identify at least one biological entity in a

biological sample recei ved from a user of the test device,

a first indicia portion configured to indicate the presence or absence of at least one medical condit ion based on identification of the at least one biological enti ty in the biological sample, and

a second indicia portion configured to display all or part of a composi te code when the first indicia portion provides an indication of the presence of the medical condition, the composite code being substantiall unique to the test device,

wherei the composite code comprises a first code portion and a second code portion, wherein the test device is configured to display at least the first code portion at the second indicia portion, only on or after providing the indication to the user of the presence or absence of the medi cal condi tion;

wherein the test device further comprises a printed circuit board and the second code portion corresponds to a serial number of the printed circuit board.

2. The device of claim 1 , comprising at least one electronic display, wherein at least the second indicia portion is provided by the at least one electronic display.

3. The device of claim 2, wherein both the first indicia portion and the second indicia portion are provided by the at least one electronic display.

4. The device of claim 3, wherei n the first and second indicia portions are provided by different regions of the same electronic display.

5. The device of any one of the preceding claims., wherein the second code portion is displayed substantially at all times.

6. The device of claim 5, wherein the second code portion is printed, embossed, etched or engraved directly on the test device or a label that is affixed to the test device.

7. The de vice of any one of the preceding claims, wherein the serial number is alphanumeric ,

8. The device of any one of the preceding claims., wherein the serial number is displayed on the printed circuit board in a human or machine-readable form.

9. The device of any one of the preceding claims, comprising an electronic display, wherein the printed circuit board comprises or is connected to a processor and the processor is programmed to cause the electronic display to display the first code portion.

.10. The device of any one of the preceding claims, wherein the device is configured to identify a plurality of different biological entities in the biological sample and selectively indicate to the user th presence of one of a plurality of medical conditions, based on identification of one of the plurality of different biological entities.

1 1. The device of claim 10, wherein the code that is displayed by the second indicia portion when the first indicia portion provides an indication of the presence of the medical condition is different depending on which of the plurality of medical conditions is present.

12. The device of claim 10 or 1 1 wherein the plurality of medical conditions are influenza A and influenza B.

1.3. A system for manufacmrmg a test device for determining the presence or absence of a medi cal condition, the system comprising:

an electronic reader adapted to read a serial number of a printed circuit board

(PCB) or an electronic input device adapted to receive input of a serial number of a PCB;

a processor adapted to associate an authentication code with the serial number of the PCB that has been read by the electronic reader or been input into the electronic input device;

a assembly mechanism for assembling the PCB into a test device such that the test device is configured to reveal the authentication code upon determining the presence of a medi cal condition.

14. The system of claim 13, wherein the assembly mechanism is arranged to configure the test device to display a code corresponding to the serial number.

15. The system of claim 13 or 1.4, wherein the serial number is provided in a barcode or QR code on the PCB and the electronic reader comprises a barcode or QR code scanner.

16. The system of claim 13, 14 or 15 wherein the electronic input device comprises a keypad.

17. A method of manufacturing a test device, the test device comprising a test portion for determining the presence or absence of a medical condition, the method comprising:

reading a serial number of a printed circuit board (PCB); associatrag an authentication code wira the serial number of the PCB:

assembling tile PCB into a test device; and

configurmg the test device to reveal the authentication code upon determining the presence of a medical condition by the test device.